Pacira Pharmaceuticals Given New $60.00 Price Target at Jefferies Group (PCRX)
Equities researchers at Jefferies Group upped their price target on shares of Pacira Pharmaceuticals (NASDAQ:PCRX) from $58.00 to $60.00 in a research report issued on Monday, StockRatingsNetwork reports. The firm currently has a “buy” rating on the stock. Jefferies Group’s target price would indicate a potential upside of 13.81% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at Barclays raised their price target on shares of Pacira Pharmaceuticals from $56.00 to $60.00 in a research note to investors on Friday. They now have an “overweight” rating on the stock. Separately, analysts at Wedbush raised their price target on shares of Pacira Pharmaceuticals from $43.00 to $59.00 in a research note to investors on Thursday, October 3rd. They now have an “outperform” rating on the stock. Finally, analysts at Brean Capital raised their price target on shares of Pacira Pharmaceuticals from $44.00 to $59.00 in a research note to investors on Thursday, October 3rd. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $55.20.
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 2.23% during mid-day trading on Monday, hitting $52.72. The stock had a trading volume of 385,437 shares. Pacira Pharmaceuticals has a 52 week low of $15.07 and a 52 week high of $55.99. The stock’s 50-day moving average is $49.0 and its 200-day moving average is $36.27. The company’s market cap is $1.759 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.30) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.35) by $0.05. The company had revenue of $23.30 million for the quarter, compared to the consensus estimate of $22.10 million. On average, analysts predict that Pacira Pharmaceuticals will post $-1.77 earnings per share for the current fiscal year.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.